Ross Kennamer-Chapman, MD
Ophthalmology · Stockbridge, GANPI 1245765601
Payments from drug & device makers
Across 83 payments — averaging $39.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ANI Pharmaceuticals, Inc.$485
- Apellis Pharmaceuticals, Inc.$452
- Regeneron Healthcare Solutions, Inc.$433
- Astellas Pharma US Inc$423
- Alimera Sciences, Inc.$420
- Genentech USA, Inc.$354
- plus $723 from 6 others
What the payments were for
- Food & beverage$3,290100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 11 | $485 |
| Apellis Pharmaceuticals, Inc. | 9 | $452 |
| Regeneron Healthcare Solutions, Inc. | 11 | $433 |
| Astellas Pharma US Inc | 9 | $423 |
| Alimera Sciences, Inc. | 11 | $420 |
| Genentech USA, Inc. | 13 | $354 |
| Mallinckrodt Hospital Products Inc. | 2 | $164 |
| AbbVie | 9 | $147 |
| Dompe US, Inc. | 1 | $125 |
| Bausch & Lomb Americas Inc. | 4 | $116 |
| Biogen | 1 | $112 |
| Coherus Oncology, Inc. | 2 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,290 in reported general payments places this provider in the 60th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 223 | $10,637 |
| Ketorolac Tromethamine | 75 | $2,681 |
| Atropine Sulfate | 70 | $2,580 |
| Brimonidine Tartrate | 38 | $1,876 |
| Difluprednate | 17 | $1,285 |
| Ciprofloxacin Hcl | 60 | $682 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $451 |
| Latanoprost | 50 | $309 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $248 |
| Timolol Maleate | 27 | $189 |
| Dorzolamide Hcl | 11 | $139 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Stockbridge
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
- Lawrence WoodardAtlanta$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.